1. Home
  2. ATAI

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Founded: 2018 Country:
Germany
Germany
Employees: N/A City: BERLIN
Market Cap: 311.4M IPO Year: 2021
Target Price: $12.00 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.24 EPS Growth: N/A
52 Week Low/High: $1.02 - $2.85 Next Earning Date: 05-15-2024
Revenue: $277,000 Revenue Growth: 2.97%
Revenue Growth (this year): -2.55% Revenue Growth (next year): 4283.99%

Share on Social Networks:

Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Johnson Anne Nagengast ATAI Chief Financial Officer Apr 2 '24 Sell $1.85 27,410 $50,708.50 73,590 SEC Form 4